Literature DB >> 32418175

Realgar (α-As4S4) Treats Myelodysplastic Syndromes through Reducing DNA Hypermethylation.

Miao Zhang1, Jia-Yi Zhang2, Ming-Qian Sun1, Peng Lu3, Jian-Xun Liu4.   

Abstract

DNA hypermethylation is an epigenetic modification that plays a critical role in the oncogenesis of myelodysplastic syndromes (MDS). Aberrant DNA methylation represses the transcription of promotors of tumor suppressor genes, inducing gene silencing. Realgar (α-As4S4) is a traditional medicine used for the treatment of various diseases in the ancient time. Realgar was reported to have efficacy for acute promyelocytic leukemia (APL). It has been demonstrated that realgar could efficiently reduce DNA hypermethylation of MDS. This review discusses the mechanisms of realgar on inhibiting DNA hypermethylation of MDS, as well as the species and metabolisms of arsenic in vivo.
© 2020. The Chinese Journal of Integrated Traditional and Western Medicine Press and Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  DNA hypermethylation; arsenic; myelodysplastic syndromes; realgar; review

Mesh:

Substances:

Year:  2020        PMID: 32418175     DOI: 10.1007/s11655-020-3263-8

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  83 in total

Review 1.  X inactivation, differentiation, and DNA methylation.

Authors:  A D Riggs
Journal:  Cytogenet Cell Genet       Date:  1975

Review 2.  Cardiac toxicity of arsenic trioxide.

Authors:  J T Barbey
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

3.  DNA modification mechanisms and gene activity during development.

Authors:  R Holliday; J E Pugh
Journal:  Science       Date:  1975-01-24       Impact factor: 47.728

4.  Treatment of bone marrow failure syndrome with integrated traditional and Western medicine.

Authors:  Rou Ma
Journal:  Chin J Integr Med       Date:  2007-06       Impact factor: 1.978

5.  Myelodysplastic syndromes: lost between two states?

Authors:  C Acquaviva; V Gelsi-Boyer; D Birnbaum
Journal:  Leukemia       Date:  2010-01       Impact factor: 11.528

Review 6.  Myelodysplastic syndrome.

Authors:  Wolf-K Hofmann; H Phillip Koeffler
Journal:  Annu Rev Med       Date:  2005       Impact factor: 13.739

7.  In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins.

Authors:  G Q Chen; J Zhu; X G Shi; J H Ni; H J Zhong; G Y Si; X L Jin; W Tang; X S Li; S M Xong; Z X Shen; G L Sun; J Ma; P Zhang; T D Zhang; C Gazin; T Naoe; S J Chen; Z Y Wang; Z Chen
Journal:  Blood       Date:  1996-08-01       Impact factor: 22.113

Review 8.  Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.

Authors:  A List; M Beran; J DiPersio; J Slack; N Vey; C S Rosenfeld; P Greenberg
Journal:  Leukemia       Date:  2003-08       Impact factor: 11.528

9.  Hypocellular myelodysplastic syndromes (MDS): new proposals.

Authors:  N Tuzuner; C Cox; J M Rowe; D Watrous; J M Bennett
Journal:  Br J Haematol       Date:  1995-11       Impact factor: 6.998

10.  DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes.

Authors:  Lanlan Shen; Hagop Kantarjian; Yi Guo; E Lin; Jianqin Shan; Xuelin Huang; Donald Berry; Saira Ahmed; Wei Zhu; Sherry Pierce; Yutaka Kondo; Yasuhiro Oki; Jaroslav Jelinek; Hussain Saba; Eli Estey; Jean-Pierre J Issa
Journal:  J Clin Oncol       Date:  2009-12-28       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.